DRTSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as DRTSW
Alpha Tau Medical Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 9, 2026
$12.62+0.33 (+2.69%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 206.0% | -61.0% | |
| Return on assets | – | – | -44.4% | |
| Current ratio | – | 22.73 | 7.45 | |
| Interest coverage | – | – | -121.9× | |
| Diluted shares | – | 40M | 81M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Alpha Tau Medical generated $100.11M from operations and spent $18.55M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$100.11M
Used
$18.55M
Capital expenditure$18.55M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$42.63M
- Cash generatingOperating cash flow above zero-$26.68M
- Return on assets improvedROA up on the prior year-29.6% → -49.4%
- Earnings backed by cashOperating cash flow above net income-$26.68M vs -$42.63M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.40 → 7.45
- No dilutionShare count did not rise70M → 81M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –